Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAE118 in Advanced Solid Tumors
NCT07787520Phase 1Not yet recruiting
- Sponsor
- Laekna
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of LAE118 in solid tumor, breast cancer, head and neck squamous cell carcinoma (HNSCC) and 1 more (3 cohorts), sponsored by Laekna. Primary endpoints: Adverse Events, Dose-Limiting Toxicities at 28 days and 16 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
LAE118
03
Conditions
solid tumorbreast cancerhead and neck squamous cell carcinoma (HNSCC)gynecologic cancer
Beyond the preview
Go deeper on NCT07787520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787520.